Raphael P H Meier1,2, Yannick D Muller2,3, Pierre-Yves Dietrich4, Jean-Christophe Tille5, Sergey Nikolaev6, Ambra Sartori6, Intidhar Labidi-Galy4, Thomas Ernandez7, Amandeep Kaur8, Hans H Hirsch8, Thomas A McKee5, Christian Toso1, Jean Villard3,7, Thierry Berney1. 1. Abdominal Transplant Surgery, Department of Surgery, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland. 2. Transplant Surgery, Department of Surgery, University of California San Francisco, San Francisco, CA. 3. Immunology and Transplant Unit, Department Diagnostic, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland. 4. Department of Oncology, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland. 5. Diagnostic Department, Geneva University Hospital, and Department of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland. 6. Department of Genetic Medicine and Development, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland. 7. Division of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland. 8. Transplantation and Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland.
Abstract
BACKGROUND: Metastatic carcinoma of a renal allograft is a rare but life threatening event with a difficult clinical management. Recent reports suggested a potential role of BK polyomavirus (BKPyV) in the development of urologic tract malignancies in kidney transplant recipients. METHODS: We investigated a kidney-pancreas female recipient with an history of BKPyV nephritis who developed a rapidly progressive and widely metastatic donor-derived renal carcinoma 9 years after transplantation. RESULTS: Histology and fluorescence in situ hybridization analysis revealed a donor-derived (XY tumor cells) collecting (Bellini) duct carcinoma. The presence of BKPyV oncogenic large tumor antigen was identified in large amount within the kidney tumor and the bowel metastases. Whole genome sequencing of the tumor confirmed multiple genome BKPyV integrations. The transplanted kidney was removed, immunosuppression was withdrawn, and recombinant interleukin-2 (IL-2) was administered for 3 months, inducing a complete tumor clearance, with no evidence of disease at 6-year follow-up. The immunological profiling during IL-2 therapy revealed the presence of donor-specific T cells and expanded cytokine-producing bright natural killer cells but no donor-specific antibodies. Finally, we found persistently elevated anti-BK virus IgG titers and a specific anti-BKPyV T cell response. CONCLUSIONS: This investigation showed evidence for the potential oncogenic role of BKPyV in collecting duct carcinoma in renal allografts and demonstrated that immunosuppression withdrawal and IL-2 therapy can lead to an efficient antitumor cellular mediated rejection possibly via 3 distinct mechanisms including (1) host-versus-graft, (2) host-versus-tumor, and (3) anti-BKPyV responses.
BACKGROUND: Metastatic carcinoma of a renal allograft is a rare but life threatening event with a difficult clinical management. Recent reports suggested a potential role of BK polyomavirus (BKPyV) in the development of urologic tract malignancies in kidney transplant recipients. METHODS: We investigated a kidney-pancreas female recipient with an history of BKPyV nephritis who developed a rapidly progressive and widely metastatic donor-derived renal carcinoma 9 years after transplantation. RESULTS: Histology and fluorescence in situ hybridization analysis revealed a donor-derived (XY tumor cells) collecting (Bellini) duct carcinoma. The presence of BKPyV oncogenic large tumor antigen was identified in large amount within the kidney tumor and the bowel metastases. Whole genome sequencing of the tumor confirmed multiple genome BKPyV integrations. The transplanted kidney was removed, immunosuppression was withdrawn, and recombinant interleukin-2 (IL-2) was administered for 3 months, inducing a complete tumor clearance, with no evidence of disease at 6-year follow-up. The immunological profiling during IL-2 therapy revealed the presence of donor-specific T cells and expanded cytokine-producing bright natural killer cells but no donor-specific antibodies. Finally, we found persistently elevated anti-BK virus IgG titers and a specific anti-BKPyV T cell response. CONCLUSIONS: This investigation showed evidence for the potential oncogenic role of BKPyV in collecting duct carcinoma in renal allografts and demonstrated that immunosuppression withdrawal and IL-2 therapy can lead to an efficient antitumor cellular mediated rejection possibly via 3 distinct mechanisms including (1) host-versus-graft, (2) host-versus-tumor, and (3) anti-BKPyV responses.
Authors: David C Müller; Maarit Rämö; Klaudia Naegele; Sebastian Ribi; Christian Wetterauer; Valeria Perrina; Luca Quagliata; Tatjana Vlajnic; Christian Ruiz; Beate Balitzki; Rainer Grobholz; Rainer Gosert; Elvis T Ajuh; Hans H Hirsch; Lukas Bubendorf; Cyrill A Rentsch Journal: J Pathol Date: 2018-02-01 Impact factor: 7.996
Authors: Yoshiyuki Takahashi; Nanae Harashima; Sachiko Kajigaya; Hisayuki Yokoyama; Elena Cherkasova; J Philip McCoy; Ken-Ichi Hanada; Othon Mena; Roger Kurlander; Abdul Tawab; Tawab Abdul; Ramaprasad Srinivasan; Andreas Lundqvist; Elizabeth Malinzak; Nancy Geller; Michael I Lerman; Richard W Childs Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: Valerie Neirynck; Kathleen Claes; Maarten Naesens; Liesbeth De Wever; Jacques Pirenne; Dirk Kuypers; Yves Vanrenterghem; Hendrik Van Poppel; Andre Kabanda; Evelyne Lerut Journal: Case Rep Nephrol Urol Date: 2012-09-05
Authors: Dominic Amara; Steven A Wisel; Hillary J Braun; Eric A Collisson; Terence Friedlander; Giulia Worner; Garret R Roll; Ryutaro Hirose; Peter G Stock Journal: Transplant Direct Date: 2020-12-08